Next Article in Journal
Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers
Next Article in Special Issue
L-Arginine/Nitric Oxide Pathway Is Altered in Colorectal Cancer and Can Be Modulated by Novel Derivatives from Oxicam Class of Non-Steroidal Anti-Inflammatory Drugs
Previous Article in Journal
Pan-Cancer Analysis of Alternative Lengthening of Telomere Activity
Previous Article in Special Issue
Cisplatin Decreases ENaC Activity Contributing to Renal Salt Wasting Syndrome

Electroporation-Based Treatments in Urology

Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland
Department of Molecular and Cellular Biology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Author to whom correspondence should be addressed.
Cancers 2020, 12(8), 2208;
Received: 29 May 2020 / Revised: 3 August 2020 / Accepted: 5 August 2020 / Published: 7 August 2020
(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
The observation that an application of a pulsed electric field (PEF) resulted in an increased permeability of the cell membrane has led to the discovery of the phenomenon called electroporation (EP). Depending on the parameters of the electric current and cell features, electroporation can be either reversible or irreversible. The irreversible electroporation (IRE) found its use in urology as a non-thermal ablative method of prostate and renal cancer. As its mechanism is based on the permeabilization of cell membrane phospholipids, IRE (as well as other treatments based on EP) provides selectivity sparing extracellular proteins and matrix. Reversible EP enables the transfer of genes, drugs, and small exogenous proteins. In clinical practice, reversible EP can locally increase the uptake of cytotoxic drugs such as cisplatin and bleomycin. This approach is known as electrochemotherapy (ECT). Few in vivo and in vitro trials of ECT have been performed on urological cancers. EP provides the possibility of transmission of genes across the cell membrane. As the protocols of gene electrotransfer (GET) over the last few years have improved, EP has become a well-known technique for non-viral cell transfection. GET involves DNA transfection directly to the cancer or the host skin and muscle tissue. Among urological cancers, the GET of several plasmids encoding prostate cancer antigens has been investigated in clinical trials. This review brings into discussion the underlying mechanism of EP and an overview of the latest progress and development perspectives of EP-based treatments in urology. View Full-Text
Keywords: ablation techniques; electrochemotherapy; electroporation; gene therapy; prostate cancer ablation techniques; electrochemotherapy; electroporation; gene therapy; prostate cancer
Show Figures

Figure 1

MDPI and ACS Style

Kiełbik, A.; Szlasa, W.; Saczko, J.; Kulbacka, J. Electroporation-Based Treatments in Urology. Cancers 2020, 12, 2208.

AMA Style

Kiełbik A, Szlasa W, Saczko J, Kulbacka J. Electroporation-Based Treatments in Urology. Cancers. 2020; 12(8):2208.

Chicago/Turabian Style

Kiełbik, Aleksander, Wojciech Szlasa, Jolanta Saczko, and Julita Kulbacka. 2020. "Electroporation-Based Treatments in Urology" Cancers 12, no. 8: 2208.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop